Humacyte Inc (HUMAW)
Official siteBIOTECHNOLOGY • NASDAQ
Last updated: Aug 26, 2026 at 5:00 PM ET
Earnings
Upcoming Estimates
Key Metrics
Technical Indicators Dashboard
As of Nov 16, 2026, the price is 89.3% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 31.7, in the neutral range between 30 and 70.
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Performance
Related GNG Research
No research available
Be the first to write about HUMAW
News
No news available
Company news will appear here when available
HUMAW Profitability: Margins, ROIC and FCF
Humacyte (HUMAW) has an operating margin of -6649.0% and a net margin of 0.0%.
- Operating margin
- -6649.0%
- Net margin
- 0.0%
- ROE
- -548.0%
Humacyte Competitors
The companies most similar to Humacyte (HUMAW) include Avita Medical, HCW Biologics and Artivion.
Sector: Healthcare
HUMAW Bull Case vs Bear Case
Bull case
- HUMAW grew quarterly revenue 34.9% year over year.
Updated Aug 13, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology
Frequently Asked Questions About HUMAW
Does HUMAW pay dividends?
Humacyte Inc (HUMAW) does not currently pay a regular dividend.
HUMAW pages: Overview, Financials
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.